|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 帕博利珠单抗治疗伴脑转移NSCLC患者的一项非随机、开放Ⅱ期试验的长期随访结果和生物标志物分析显示文摘背景与目的我们开展了一项帕博利珠单抗用于伴未治疗脑转移的非小细胞肺癌(non-small cell lung cancer,NSCLC)或黑色素瘤患者的疗效和安全性的II期试验,旨在评估程序性死亡受体1(programmed cell death 1,PD-1)抑制剂在中枢神经系统(central nervous system,CNS)中的疗效。中期结果已发表,现报道对NSCLC队列的更新分析结果。方法这是一项开放性、单中心、II期试验。纳入标准:年龄≥18岁,诊断为晚期NSCLC并伴有≥1个5 mm-20 mm脑转移病灶,既往从未治疗或之前放疗后进展,无神经系统症状,不需要激素治疗且美国东部肿瘤协作组(Eastern Cooperative Oncology Group,ECOG)<2分。患者每2周接受一次帕博利珠单抗(10 mg/kg)治疗。队列1为程序性死亡配体1(programmed cell death ligand 1,PD-L1)≥1%的患者,队列2为PD-L1<1%或未评估的患者。主要终点是脑转移患者缓解比例。所有经治患者均纳入疗效与安全性终点的分析。该研究已结束入组,并于Clinicaltrials.gov登记注册,注册号为NCT02085070。结果2014年3月31日-2018年5月21日,共42例患者接受治疗。中位随访时间为8.3个月(IQR:4.5个月-26.2个月)。队列1的37例患者中11例有脑转移缓解[29.7%(95%CI:15.9%-47.0%)]。队列2未观察到缓解。治疗相关的3级-4级不良事件(adverse events,AEs)包括2例肺炎、1例全身症状、1例结肠炎、1例肾上腺皮质功能不全、1例高血糖症和1例低钾血症。6例(14%)患者发生了治疗相关的严重不良事件,包括肺炎、急性肾损伤、低钾血症和肾上腺皮质功能不全。没有观察到治疗相关死亡病例。结论帕博利珠单抗治疗PD-L1≥1%的NSCLC伴脑转移患者有效,且对所有纳入的未经治疗的脑转移患者安全。需要进一步探索免疫治疗用于NSCLC合并CNS转移。 | Sarah B GOLDBERG Kurt A SCHALPER Scott N GETTINGER Amit MAHAJAN Roy S HERBST Anne C CHANG Rogerio LILENBAUM Frederick H WILSON Sacit Bulent OMAY James B YU Lucia JILAVEANU Thuy TRAN Kira PAVLIK Elin ROWEN Heather GERRSH Annette KOMLO Richa GUPTA Hailey WYATT Matthew RIBEIRO Yuval KLUGER Geyu ZHOU Wei WEI Veronica L CHANG Harriet M KLUGER 董晓荣(翻译/校对) | 2021 | 中国肺癌杂志2021，24，9： | 34 |
| 2 | 非胰岛素依赖型糖尿病冠状动脉疾病的危险因素:英国糖尿病前瞻性研究(UKPDS:23)显示文摘目的:评价2型糖尿病患者冠状动脉疾病的基线危险因素。设计:对2 693例资料完整的患者进行年龄和性别调整的逐步选择过程分析,以确定哪些冠状动脉疾病的危险因素应纳入 Cox 比例风险模型。对象:3 055例白人患者,平均年龄52岁,均新近诊断为2型糖尿病,且无动脉粥样硬化相关疾病的证据。平均随访期7.9年。335例患者于10年内出现冠状动脉疾病。结局评定:具有明确异常心电图的心绞痛、致死或非致死性心肌梗塞。结果:冠状动脉疾病与低密度脂蛋白胆固醇浓度升高、高密度脂蛋白胆固醇浓度降低、甘油三酯浓度升高、高血红蛋白 A_(1c)、高收缩压、高空腹血糖以及吸烟史密切相关。低密度脂蛋白胆固醇较高1/3对较低1/3区间的估计风险比为2.26(95%可信区间为1.70~3.00),高密度脂蛋白胆固醇为0.55(0.41~0.73),血红蛋白 A_(1c)为1.52(1.15~2.01),收缩压为1.82(1.34~2.47)。吸烟者的估计风险比为1.41(1.06~1.88)。结论:2型糖尿病患者中,存在冠状动脉疾病潜在的、可变的5种危险因素的交叉重叠影响。它们是低密度脂蛋白胆固醇浓度升高、高密度脂蛋白胆固醇浓度降低、高血压、高血糖和吸烟。 | R C Turner H Millns H A W Neil I M Stratton S E Manley D R Matthews R R Holman 赵维纲 | 1998 | 英国医学杂志中文版1998，0，3： | 11 |
| 3 | 文献快报(6):青少年数字媒体使用与后续注意缺陷多动障碍症状关联显示文摘现代数字媒体平台具有易获得性和强烈的刺激性,频繁使用现代数字媒体是否与青少年注意缺陷多动障碍(ADHD)症状存在关联尚未明确。一项来自南加卅I大学的纵向队列研究通过方便抽样的方法,对从洛杉矶10所高中招募的4100名15—16岁青少年开展为期24个月的随访调查(2014年9月至2016年12月,每6个月进行1次),基线调查共纳入3051名十年级学生。 | CHAELIN K R JUNHAN C H MATTHEW D S 陶心琢 陶舒曼 | 2018 | 中国学校卫生2018，39，8： | 6 |
| 4 | Metabolic and hepatic effects of liraglutide,obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis显示文摘AIM To evaluate the pharmacodynamics of compounds in clinical development for nonalcoholic steatohepatitis(NASH) in obese mouse models of biopsy-confirmedNASH.METHODS Male wild-type C57 BL/6 J mice(DIO-NASH) and Lep^(ob/ob)(ob/ob-NASH) mice were fed a diet high in trans-fat(40%), fructose(20%) and cholesterol(2%) for 30 and 21 wk, respectively. Prior to treatment, all mice underwent liver biopsy for confirmation and stratification of liver steatosis and fibrosis, using the nonalcoholic fatty liver disease activity score(NAS) and fibrosis staging system. The mice were kept on the diet and received vehicle, liraglutide(0.2 mg/kg, SC, BID), obeticholic acid(OCA, 30 mg/kg PO, QD), or elafibranor(30 mg/kg PO, QD) for eight weeks. Within-subject comparisons were performed on changes in steatosis, inflammation, ballooning degeneration, and fibrosis scores. In addition, compound effects were evaluated by quantitative liver histology, including percent fractional area of liver fat, galectin-3, and collagen 1 a1.RESULTS Liraglutide and elafibranor, but not OCA, reduced body weight in both models. Liraglutide improved steatosis scores in DIO-NASH mice only. Elafibranor and OCA reduced histopathological scores of hepatic steatosis and inflammation in both models, but only elafibranor reduced fibrosis severity. Liraglutide and OCA reduced total liver fat, collagen 1 a1, and galectin-3 content, driven by significant reductions in liver weight. The individual drug effects on NASH histological endpoints were supported by global gene expression(RNA sequencing) and liver lipid biochemistry.CONCLUSION DIO-NASH and ob/ob-NASH mouse models show distinct treatment effects of liraglutide, OCA, and elafibranor, being in general agreement with corresponding findings in clinical trials for NASH. The present data therefore further supports the clinical translatability and utility of DIO-NASH and ob/ob-NASH mouse models of NASH for probing the therapeutic efficacy of compounds in preclinical drug development for NASH. | Kirstine S Tolbol Maria NB Kristiansen Henrik H Hansen Sanne S Veidal Kristoffer TG Rigbolt Matthew P Gillum Jacob Jelsing Niels Vrang Michael Feigh | 2018 | World Journal of Gastroenterology2018，24，2： | 5 |
| 5 | Porous chitosan scaffolds for tissue engineering显示文摘 | Madihally S V Matthew H W T | | 0，，： | 2 |
| 6 | Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study显示文摘 | Nauck Michael Frid Anders Hermansen Kjeld Shah Nalini S Tankova Tsvetalina Mitha Ismail H Zdravkovic Milan Düring Maria Matthews David R | 2009 | Diabetes Care2009，，： | 2 |
| 7 | Mucoepidemoid carcinoma in a patient with congenital agenesis of the left upper lobe 显示文摘 | Pandya H Matthews S | 2003 | Br Radiol2003，76，： | 1 |
| 8 | Categorization of Scope 3 Emissions for Streamlined Enterprise Carbon Footprinting 显示文摘 | Huang Y A Weber C L Matthews H S | 2009 | Environmental Science & Technology2009，43，22： | 1 |
| 9 | Tumorigenesissuppressor Pdcd4 dow n-regulates mitogen-activated pro-tein kinase 1 expression to suppress colon carcinoma cellinvasion显示文摘 | Yang H S Matthews C P Clair T | 2006 | Mol Cell Biol2006，26，4： | 1 |
| 10 | The Nature and Biosynthesis of the Carotenoids of Different Color Varieties of Capsicum annuum显示文摘 | B H Davies S Matthew J T O Kirk | 1970 | Phytochemistry1970，，9： | 1 |
| 11 | Evaluation of the biocompatibility of a chitosan scaffold in mice显示文摘 | vander Vord P J Matthew H W DeSilva S P et aI | 2002 | Biomed Mater Res2002，59，3： | 1 |
| 12 | Embodied environment emissions in U S international trade: 1997-2004 显示文摘 | Weber C L Matthews H S | 2007 | Environmental Science and Technology2007，41，14： | 1 |
| 13 | Embodied environmental emissions in US international trade, 1997-2004 显示文摘 | Weber C L Matthews H S | 2007 | Environmental Science & Technology2007，41，14： | 1 |
| 14 | Adaptation of HIV-1to human leukocyte antigen class I显示文摘 | Kawashima Y Pfafferott K Frater J Matthews P Payne R Addo M Gatanaga H Fujiwara M Hachiya A Koizumi H Kuse N Oka S Duda A Prendergast A Crawford H Leslie A Brumme Z Brumme C Allen T Brander C Kaslow R Tang J Hunter E Allen S Mulenga J Branch S Roach T John M Mallal S Ogwu A Shapiro R Prado J G Fidler S Weber J Pybus O G Klenerman P Ndung'u T Phillips R Heckerman D Harrigan P R Walker B D Takiguchi M Goulder P | 2009 | Nature2009，458，7238： | 1 |
| 15 | The Importance of Carbon Footprint Estimation Boundaries 显示文摘 | Matthews H S Hendrickson C T Weber C L | 2008 | Environmental Science & Technology2008，42，16： | 1 |
| 16 | Recycling Steel from Grinding Swarf 显示文摘 | Fu H Matthews M A Langdon S W | 1998 | Waste Management1998，18，5： | 1 |
| 17 | Embodied Environmental Emissions in US International Trade 1997 - 2004 显示文摘 | Weber C L Matthews H S | 2007 | Environmental Science and Technology2007，41，： | 1 |
| 18 | Brown and beige fat: development, function and therapeutic potential显示文摘 | Matthew H Patrick S | 2013 | Nat Med2013，19，10： | 1 |
| 19 | Elemental fluorine Part 12 fluorination of 1,4 - disubstituted aromatic compounds显示文摘 | Richard D C John H Matthew E S | 2000 | J Fluorine Chem2000，102，12： | 1 |
| 20 | Comparative Life- cycleAir Emissions of Coal,Domestic Natural Gas,LNG,and SNG forElectricity Generation 显示文摘 | Jaramillo P Griffin W M Matthews H S | 2007 | Environmental Science & Technology2007，41，17： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员